Drug Profile
Osemozotan
Alternative Names: MKC-242; MN-305Latest Information Update: 21 May 2014
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Antidepressants; Anxiolytics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Anxiety disorders; Generalised anxiety disorder; Insomnia; Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 08 May 2014 Osemozotan is no longer licensed to MediciNova (http://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1403.pdf)
- 08 May 2014 Suspended - Phase-II for Anxiety disorders in Japan (PO)
- 08 May 2014 Suspended - Phase-II for Insomnia in USA (PO)